GLMDのROE（自己資本利益率）は？

Galmed Pharmaceuticals LTDのROEは-96.34%です。

GLMDの配当利回りは？

Galmed Pharmaceuticals LTDの配当利回りは0.00%です。

GLMDの品質スコア（Quality Score）は？

当社のAIはGLMDの総合財務品質を100点中8点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。

GLMDは今が買い時ですか？

当社AIのタイミングスコアは100点中66点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。

GLMDはどのセクターに属しますか？

Galmed Pharmaceuticals LTDはHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）

GLMD (NASDAQ) 株価分析 | GALMED PHARMACEUTICALS LTD

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-06-30)

GLMD AI Analysis Summary

Our AI summary for GLMD: Galmed Pharmaceuticals LTD (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -96.34%, a dividend yield of 0.00%. Its financial Quality Score stands at 8/100 — fundamentals below the market average. The AI Timing Score is 66/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

GLMD

Galmed Pharmaceuticals LTD

US:NASDAQ STOCK Healthcare >> Biotechnology News 94

USD 0.62

0.02 (3.67%) Day Change

Watchlist Portfolio Compare Chart

0.15

D/E

-96.3%

ROE

-83.9%

ROA

0.00%

Div Yield

GALMED PHARMACEUTICALS LTD
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 0.62 Price 0.02 (3.67%) Day Change	NEWS SCORE: 94

GLMD, ファンダメンタルスコアはnot good ( ファンダメンタル = 8) そしてテクニカルスコアは ...(Sign In to See)...

Loading chart...

8 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROEが昨年度比で低い
ROAがROEに比べて低い
ROAの伸びが低い
Last-year ROA is lower than last-2-years ROA.
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...

Deepscope 分析

48%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	94
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	0.62
PBV / Sector	0.35 / 5.20 GREAT
Earning Per Share	-1.69

PE / Sector	N/A / 19.97
PEG or PE/Growth / Sector	N/A / 1.22
Average 1M Daily Value	0.52 M GREAT
Average 1W Daily Value	0.39 M GREAT

Timing Factors

71%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

ポイントになる統計

37%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	N/A / 98.71
NPM Average (%) / Sector	N/A / -1,721.76
NPM Change Average (%) / Sector	N/A / 5,211.62
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-83.85 / 27.02
ROA Average (%) / Sector	-65.85 / -368.17
ROA Change Average (%) / Sector	6.00 / 5,404.12
ROE (%) / Sector	-96.34 / 3.47
ROE Average (%) / Sector	-78.12 / 6.51
ROE Change Average (%) / Sector	4.81 / 2,128.13
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

配当

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -1.75

登録情報

Analyze Date	2026-08-01 07:59:54
Symbol	GLMD
Name	GALMED PHARMACEUTICALS LTD
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	8.26 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	4.95 / 9,903.94

ニュース

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 16 Abba Hillel Road, Ramat Gan, Israel, 5250608

Phone: 972 3 693 8448

Website: https://galmedpharma.com

Sector: Healthcare >> Biotechnology

Description: Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases and related indications. The company develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in a Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through the ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company is developing MyBiotics, which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform and Tissue Dynamics to develop a novel human chronic cardiac fibrosis model. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.